Dive into additional groundbreaking treatment approaches for triple-negative breast cancer (TNBC) in this tumor board, the second in a series focused on TNBC. This multidisciplinary tumor board discusses a patient with advanced TNBC and how novel anti-TROP2 antibody drug conjugates (ADCs) therapy may play a role.
Educational Partner: The Academy for Continued Healthcare Learning (ACHL)
Medium: Online Presentation
Commercial Support: Support for this activity has been provided through educational grants from Gilead Sciences Inc.
Sponsored by the University of Chicago Pritzker School of Medicine and the Academy for Continued Healthcare Learning (ACHL).
Overview
Syllabus
At the conclusion of this activity, participants will be able to:
- Discuss new targeted treatment approaches in the setting of TNBC;
- Discuss the role of ADC therapies and TROP2 for triple-negative breast cancer.
